Accession Number : ADA537750


Title :   High Dose Atorvastatin Decreases Cellular Markers of Immune Activation Without Affecting HIV-1 RNA Levels: Results of a Double-Blind Randomized Placebo Controlled Clinical Trial


Descriptive Note : Journal article


Corporate Author : NAVAL MEDICAL CENTER SAN DIEGO CA


Personal Author(s) : Ganesan, Anuradha ; Crum-Cianflone, Nancy ; Higgins, Jeanette ; Qin, Jing ; Rehm, Catherine ; Metcalf, Julia ; Brandt, Carolyn ; Vita, Jean ; Decker, Catherine F ; Sklar, Peter ; Bavaro, Mary ; Tasker, Sybil ; Follmann, Dean ; Maldarelli, Frank


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/a537750.pdf


Report Date : 15 Feb 2011


Pagination or Media Count : 10


Abstract : Antiretroviral therapy (ART) has transformed our clinical approach to human immunodeficiency virus (HIV) infection. Despite substantial advances in the management of HIV infection, concerns about transmitted drug resistance, ART-related toxic effects, and the consequences of chronic inflammation persist, emphasizing the need for ongoing research into alternate therapeutic targets and strategies to modulate the chronic immune activation/inflammation observed in this disease [1?3]. Strategies that block key interactions between the host and the virus, including those that target lipid rafts, are an area of interest. Lipid rafts are plasma membrane microdomains rich in sphingolipids and cholesterol that play a critical role in the replication of HIV type 1 (HIV-1) [4, 5]. In vitro models suggest that disruption of lipid rafts with cholesterol-depleting agents, such as 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins), reduces HIV-1 particle production [5].


Descriptors :   *HUMAN IMMUNODEFICIENCY VIRUSES , *RETROVIRUSES , CLINICAL MEDICINE , CHOLESTEROL , CHEMICAL AGENTS , MARKERS , CLINICAL TRIALS , INFLAMMATION , LIPOPROTEINS , RIBONUCLEIC ACIDS , CREATINE PHOSPHOKINASE , LIPIDS , CELLS , INFECTIOUS DISEASES


Subject Categories : Medicine and Medical Research


Distribution Statement : APPROVED FOR PUBLIC RELEASE